Literature DB >> 11122981

New developments in panic disorder.

P C Marzol1, M H Pollack.   

Abstract

Panic disorder is a distressing and disabling disorder characterized by recurring panic attacks; anticipatory anxiety about having additional attacks; and agoraphobic fear and avoidance of situations in which attacks have occurred, ready escape is difficult, or help is unavailable in the event of an attack. It is typically associated with impairment in social, emotional, and vocational functioning, as well as excessive utilization of the medical care system. A number of pharmacologic agents and cognitive-behavioral treatments have proven effective for the treatment of panic disorder. Selective serotonin reuptake inhibitors are becoming first-line pharmacotherapy because of their favorable side effect profile and greater spectrum of efficacy in comparison with older classes of agents. In this article, we provide an overview of the prevalence, associated health care utilization, impairment in quality of life, and treatment of panic disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122981     DOI: 10.1007/s11920-000-0081-8

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  49 in total

1.  Is placebo response the same as drug response in panic disorder?

Authors:  M H Rapaport; M Pollack; R Wolkow; J Mardekian; C Clary
Journal:  Am J Psychiatry       Date:  2000-06       Impact factor: 18.112

2.  Group cognitive-behavior therapy for patients failing to respond to pharmacotherapy for panic disorder: a clinical case series.

Authors:  M W Otto; M H Pollack; S J Penava; B G Zucker
Journal:  Behav Res Ther       Date:  1999-08

Review 3.  SSRIs in the treatment of panic disorder.

Authors:  A W Goddard; D S Charney
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

4.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

5.  Quality of life in patients with panic disorder.

Authors:  P J Candilis; R Y McLean; M W Otto; G G Manfro; J J Worthington; S J Penava; P C Marzol; M H Pollack
Journal:  J Nerv Ment Dis       Date:  1999-07       Impact factor: 2.254

6.  Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial.

Authors:  D H Barlow; J M Gorman; M K Shear; S W Woods
Journal:  JAMA       Date:  2000-05-17       Impact factor: 56.272

7.  Empirically supported treatments for panic disorder: costs, benefits, and stepped care.

Authors:  M W Otto; M H Pollack; K M Maki
Journal:  J Consult Clin Psychol       Date:  2000-08

8.  An open-label trial of nefazodone in high comorbidity panic disorder.

Authors:  N A DeMartinis; E Schweizer; K Rickels
Journal:  J Clin Psychiatry       Date:  1996-06       Impact factor: 4.384

9.  Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.

Authors:  J Endicott; J Nee; W Harrison; R Blumenthal
Journal:  Psychopharmacol Bull       Date:  1993

10.  Rate of improvement during cognitive-behavioral group treatment for panic disorder.

Authors:  S J Penava; M W Otto; K M Maki; M H Pollack
Journal:  Behav Res Ther       Date:  1998 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.